Carl Weissman serves concurrently as Chairman and CEO of Accelerator and as a Managing Director at OVP.  Carl joined OVP as a Venture Partner in 2007 and became a Managing Director in 2009.  He focuses on the digital biology sector, with investments including Allozyne, Fate Therapeutics and Novomer.  He is also a Board Observer to AdmitOne, Limerick BioPharma, NanoString, Verdezyne and Viral Logic Systems Technology (VLST).

Carl led the formation of Accelerator in 2003.  Accelerator is a joint investment vehicle backed by a syndicate of venture capital firms, including OVP, which invests in and actively manages emerging biotechnology companies.  Accelerator has facilitated Series A investments in, and has managed or is currently managing the operations of ten OVP portfolio companies.  Four companies have successfully graduated from Accelerator and between them raised $144M. Two of these companies - Allozyne and VLST - are currently OVP portfolio companies.

Prior to joining OVP, Carl was a Venture Partner at MPM Capital from 2001 through 2006.  While at MPM, he served as President and CEO of Centagenetix, a human genetics company in Cambridge, MA.  Carl led the 2003 merger of Centagenetix with Elixir Pharmaceuticals, catalyzing a $40M Series B financing in the combined company.  Prior to joining MPM, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development.

Carl serves on the Board of the Washington Biotechnology and Biomedical Association (WBBA) and the Oregon Translational Research and Drug Development Institute (OTRADI), and spent from 2004-2009 on the Board and as Board President of Teens In Public Service.